The foreign envoys, who traveled to Hyderabad on Wednesday to visit two biotech companies working on Covid-19 vaccines, said they are impressed by the progress made by Indian pharmaceutical companies. The group of 60 envoys visited the facilities of two companies: Bharat Biotech and Biological E.
“I was very impressed to see how far you have come, how dedicated you are to fighting Covid, how focused you are on helping humanity. It is not just a commercial or national overriding interest. You are really connecting with the world and helping all of us, ”said F Svane, Danish ambassador to India, according to the ANI news agency.
Australian Ambassador Barry O’Farrell said that India has the manufacturing capacity to produce sufficient quantities to meet the demands of citizens in all countries.
“Many vaccines are being produced in countries around the world, but there is only one country that has the manufacturing capacity to produce sufficient quantities to meet the demands of citizens in all countries and that is India,” ANI quoted O ‘ Farrell.
He also tweeted, “#Hyderabad, Flag of India’s vaccine center, produces one-third of all vaccines manufactured globally. He witnessed first-hand the impressive research and manufacturing facilities at Bharat Biotech and Biological E. Limited and the progress India is making in its COVID vaccine efforts. Thanks to MEA India. “
During her visit to Bharat Biotech, the company’s Deputy General Manager, Suchitra Ella, briefed the ambassadors on the development of Covaxin.
Suchitra said that Covaxin had sparked the interest of several countries around the world for the supplies and introduction. “It is an honor to have with us all the distinguished ambassadors from various countries. We are proud to note that the world is looking to India in the common fight against this deadly pandemic, ”he said.
The delegation was led by MEA and comprised of high commissioners and government representatives from Asia, Africa, Europe, North America, South America and Oceania.
The president and managing director of Bharat Biotech, Dr. Krishna Yella, also briefed the delegation on the company’s vaccine development program, in collaboration with the Indian Council for Medical Research (ICMR) and the National Institute of Virology ( NIV).
Yella, who heads Covaxin’s research, development, clinical trials, and production teams, explained the company’s research process, manufacturing capabilities, and expertise. He gave virtual and physical tours of the facilities.
India is the world’s largest vaccine manufacturer and has contributed significantly to global efforts against the Covid-19 pandemic.
Prime Minister Narendra Modi had previously said that India’s vaccine production and delivery capacity will be used to help all of humanity fight this crisis. He had visited Zydus Biotech Park in Ahmedabad, Bharat Biotech in Hyderabad, and Serum Institute of India (SII) in Pune on November 28 to carry out a comprehensive review of the vaccine development and manufacturing process.
Bharat Biotech had applied for an emergency use authorization on Monday for its indigenously developed Covaxin. It is the second Indian company to apply for an emergency use authorization after SII applied for such use for the vaccine developed by the University of Oxford and AstraZeneca.
.
